What is Sciwind Biosciences?
Sciwind Biosciences operates as a specialized biopharmaceutical entity dedicated to the discovery and development of innovative therapies. Headquartered in Hangzhou, China, the company focuses on addressing significant unmet medical needs through a rigorous, science-led approach to drug discovery. By maintaining a lean, clinical-stage operational model, Sciwind Biosciences effectively bridges the gap between early-stage research and commercial-ready therapeutic solutions. Its market position is defined by a commitment to high-impact R&D, targeting complex disease pathways that require sophisticated pharmacological intervention. The firm's strategic focus remains on building a sustainable, high-value portfolio that attracts top-tier institutional backing.
How much funding has Sciwind Biosciences raised?
Sciwind Biosciences has raised a total of $70M across 1 funding round:
Series C
$70M
Series C (2021): $70M with participation from LYFE Capital, Loyal Valley Capital, and IDG Capital Partners
Key Investors in Sciwind Biosciences
LYFE Capital
LYFE Capital is a premier healthcare investment platform that connects healthcare champions with global markets, supply chains, and strategic partners, focusing on critical healthcare assets and next-generation R&D services.
Loyal Valley Capital
Loyal Valley Capital is a thematic, research-oriented private equity firm that acts as a partner of choice for China's most promising companies, with a history of backing industry leaders across various high-growth sectors.
IDG Capital Partners
IDG Capital is a long-standing investment firm established in 1992 that specializes in developing companies through private equity, venture capital, and strategic mergers and acquisitions.
What's next for Sciwind Biosciences?
With the successful closure of this major strategic investment, Sciwind Biosciences is poised to scale its operational capacity and expedite its clinical trial timelines. The company's forward-looking strategy involves the systematic advancement of its therapeutic candidates, with a clear emphasis on achieving key data readouts that will inform future commercialization efforts. Furthermore, the firm is expected to utilize these funds to strengthen its internal R&D infrastructure and potentially explore strategic partnerships that could enhance its global reach. As the biopharmaceutical sector continues to evolve, Sciwind Biosciences remains focused on maintaining its competitive edge through disciplined capital allocation and a relentless pursuit of scientific excellence in its core therapeutic areas.
See full Sciwind Biosciences company page
